BGB 16673-104

Hematological neoplasms
Other indications (e.g. myeloproliferative diseases), Non-Hodgkin lymphoma, Non-Hodgkin lymphoma (incl. CLL)
Second line + Treatment
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies